Biotech & Bioprocessing

Can Fibril-Depleting Therapies Transform Rare Disease Treatment?
Biotech & Bioprocessing Can Fibril-Depleting Therapies Transform Rare Disease Treatment?

What if a hidden enemy within the body, silently damaging vital organs, could finally be dismantled with precision? For thousands battling rare diseases like AL amyloidosis, where toxic protein deposits wreak havoc on the heart and kidneys, this prospect is no longer a distant dream. A

How Can Engineered Exosomes Transform Targeted Therapies?
Biotech & Bioprocessing How Can Engineered Exosomes Transform Targeted Therapies?

Picture a medical landscape where treatments can slip past the body's toughest defenses, delivering healing payloads directly to diseased cells without harming the surrounding healthy tissue. This isn't science fiction but the tantalizing promise of engineered exosomes—tiny biological couriers that

Junevity's siRNA Platform Targets Metabolic Disorders
Biotech & Bioprocessing Junevity's siRNA Platform Targets Metabolic Disorders

Imagine a world where a single treatment could manage type 2 diabetes or obesity for months at a time, freeing patients from the burden of daily medications and the frustrating cycle of weight regain. This isn’t a distant dream but a potential reality being shaped by Junevity, a biotechnology

How Does Automation Transform Allogeneic Cell Therapy?
Biotech & Bioprocessing How Does Automation Transform Allogeneic Cell Therapy?

What if a single batch of cells could save thousands of lives without the wait and expense of custom-made treatments? This isn’t a distant dream but a tangible reality unfolding in the realm of allogeneic cell therapy, where “off-the-shelf” solutions derived from donor cells are poised to

Rentschler and Coriolis Unite for Biopharma Innovation
Biotech & Bioprocessing Rentschler and Coriolis Unite for Biopharma Innovation

What if the complex journey of turning a groundbreaking biologic into a life-saving therapy could be transformed into a streamlined, efficient process? In a world where biopharmaceutical development faces unprecedented challenges, a powerful collaboration between Rentschler Biopharma and Coriolis

How Is FDA Shifting to Human-Relevant Drug Safety Models?
Biotech & Bioprocessing How Is FDA Shifting to Human-Relevant Drug Safety Models?

Imagine a world where life-saving drugs reach patients faster, with fewer animals harmed and costs slashed by millions. This isn’t a distant dream but a tangible goal as the U.S. Food and Drug Administration (FDA) pivots toward human-relevant drug safety models. With new draft guidance released

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later